MDGL

Madrigal Pharmaceuticals Inc

Halal Rating :
Comfortable
Last Price $302.04 Last updated:
Market Cap -
7D Change -0.55%
1 Year Change 29.53%

Company Overview

Industries
  • Manufacturing
  • Pharmaceutical Products
  • Pharmaceutical Preparations
Exchange
Next Earnings Date

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of fatty liver disease. Their lead product candidate, resmetirom, is being developed for the treatment of NASH (non-alcoholic steatohepatitis), a serious liver condition that can lead to cirrhosis.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $62.17m $182.16m - $3.68m 0.00% 2.02%
June 30, 2024 $14.64m $180.83m - $3.66m 0.00% 2.02%

Company Impact

Help us evaluate Madrigal Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Recent News & Updates